ROR1 and neoplasm: In murine models of melanoma and pancreatic cancer, treatment of cytotoxic T lymphocytes and ROR1‐targeting CAR T cells with butyrate and pentanoate resulted in elevated production of effector molecules such as CD25, IFN‐γ and TNF‐α leading to improved anti‐tumour immunity and reduced tumour volume and weight compared to untreated cells.14